StockNews.AI
PEPG
StockNews.AI
15 days

PepGen Inc. Class Action: The Gross Law Firm Reminds PepGen Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 8, 2025 - PEPG

1. PepGen faces class action alleging misleading statements about PGN-EDO51's effectiveness. 2. Complaints suggest serious safety concerns with the CONNECT2 study. 3. Shareholders invited to register for potential lead plaintiff status in the case. 4. Class period for claims spans from March 7, 2024 to March 3, 2025. 5. Legal action could significantly impact PepGen's stock and public perception.

5m saved
Insight
Article

FAQ

Why Very Bearish?

Misleading statements and safety concerns could decrease investor confidence. Similar past cases show stock drops post-legal actions.

How important is it?

The severe nature of the allegations and potential legal repercussions are highly relevant to PEPG's future.

Why Long Term?

The ongoing legal proceedings and potential implications on FDA approval could have lasting effects on stock value.

Related Companies

AMGNBIIBREGN
, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of PepGen Inc. (NASDAQ: PEPG). Shareholders who purchased shares of PEPG during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE:https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=159213&from=4  CLASS PERIOD: March 7, 2024 to March 3, 2025 ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the Company's lead product candidate, PGN-EDO51, was less effective and safe than defendants had led investors to believe; (ii) phase two, CONNECT2 study was dangerous or otherwise deficient for purposes of U.S. Food and Drug Administration ("FDA") approval; (iii) as a result of all the foregoing, PepGen was likely to halt the CONNECT2 study, and PGN-EDO51's clinical, regulatory, and commercial prospects were overstated; and (iv) as a result, defendants' public statements were materially false and misleading at all relevant times. DEADLINE: August 8, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/pepgen-inc-loss-submission-form/?id=159213&from=4  NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of PEPG during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 8, 2025. There is no cost or obligation to you to participate in this case. WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes. CONTACT:The Gross Law Firm15 West 38th Street, 12th floorNew York, NY, 10018Email: [email protected] Phone: (646) 453-8903 SOURCE The Gross Law Firm WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News